SymphoRNA Email Formats

About SymphoRNA

SymphoRNA is pioneering multi-target RNA medicines to treat the world’s most complex diseases. Most drugs focus on single targets, yet 70% of diseases involve multiple pathways. This is why so many treatments fail or deliver only limited benefit. Tackling complexity requires a new approach. In 2021, we developed a polysaccharide-based delivery system — safe, precise, and affordable, with proven in vivo performance. Unlike traditional lipid systems, it avoids PEG, is biodegradable, stable for 50+ days at room temperature, and capable of carrying multiple RNAs at once (mRNA, saRNA, siRNA). On this foundation, we built our therapeutic engine: programmable RNA “cocktails” that combine and tune multiple pathways at once, accelerated by AI-driven design. We are advancing our first programs in idiopathic pulmonary fibrosis while building a broader pipeline across fibrotic, inflammatory, and aging-related diseases. Our mission is clear: succeed where single-target approaches fail — and turn complexity into possibility for patients worldwide.

View contact profiles from SymphoRNA